title: TRPV1 antagonists: clinical setbacks and prospects for future development.
authors.affiliation: Abbott Laboratories, Neuroscience Disease Research, Abbott Park, IL, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Kort
authors.forename: Philip R
authors.initials: PR
authors.lastname: Kym
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology*; D052160:Benzothiazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001833:Body Temperature Regulation / Q000187:drug effects; D006801:Humans; D007191:Indazoles / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D011759:Pyrrolidines / Q000494:pharmacology*; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors*; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C528492:ABT 102; C574562:AZD1386; D018712:Analgesics, Non-Narcotic; D001562:Benzimidazoles; D052160:Benzothiazoles; D007191:Indazoles; C574563:MK-2295; C523409:N-(4-(6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy)benzothiazol-2-yl)acetamide; D011725:Pyridines; D011743:Pyrimidines; D011759:Pyrrolidines; C512301:SB 705498; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D014508:Urea